In our study, we found targeting VSIG4+ TAMs by VSIG4 deficiency or blockade remarkably limited tumor growth and metastasis, especially those derived from anaplastic thyroid cancer (ATC) and pancreatic cancer, two extremely aggressive types. This evidence concerns the gene VSIG4 and thyroid gland undifferentiated (anaplastic) carcinoma.